INVO Fertility ( (IVF) ) has released a notification of late filing.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
INVO Fertility, Inc. has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending March 31, 2025. The primary reason for the delay is the additional time required to finalize financial statements. INVO Fertility anticipates filing the report within a 5-day extension period. The company expects a significant financial impact, with a net loss increase of approximately $15.8 million compared to the same period last year, mainly due to an impairment related to the NAYA Therapeutics acquisition. INVO Fertility is committed to ongoing compliance efforts, as indicated by the signature of CEO Steve Shum on the notification.
The most recent analyst rating on (IVF) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on INVO Fertility stock, see the IVF Stock Forecast page.
Spark’s Take on IVF Stock
According to Spark, TipRanks’ AI Analyst, IVF is a Underperform.
NAYA Biosciences’ strong revenue growth is overshadowed by financial instability and lack of profitability. Technical indicators show weak performance, and valuation is unattractive. The absence of significant corporate events or earnings call insights limits positive outlook adjustments.
To see Spark’s full report on IVF stock, click here.
More about INVO Fertility
Average Trading Volume: 2,246,268
Technical Sentiment Signal: Sell
Current Market Cap: $2.11M
See more insights into IVF stock on TipRanks’ Stock Analysis page.